- Multiple Strategies to Leverage Existing Work to Understand Toxicant Contributors to Autism: Lessons from the Autism Data Science Initiative
-
Stars at Night Ballroom B4‚ Convention Center
Chair: Nicole Kleinstreuer, NIH
Co-Chair: Cindy Lawler, NIEHS
Primary Endorser: Neurotoxicology Specialty Section
Endorser(s): Reproductive and Developmental Toxicology Specialty Section
Endorser(s): Clinical and Translational Toxicology Specialty SectionAbout 1 in 31 children in the United States have been identified with autism, which affects approximately 3-4 males for every female (CDC, 2025). Advancing our understanding of autism has been identified as a strategic priority for the National Institutes of Health (NIH). Core features of autism are difficulties with social communication, social interaction and restricted, repetitive patterns of behavior or interests. Autism can be reliably diagnosed by experienced healthcare specialists as early as age 2. It is an extremely heterogeneous condition with a variable clinical presentation and differing service and support needs. Likewise, studies of autism in tens of thousands of people have revealed a complex genetic architecture, including associations with single-gene disorders or aneuploidies, rare de novo copy number variants, single nucleotide variants, and heritable common polygenic risks. Nongenetic factors (e.g., environmental chemicals, nutritional factors, medications) also contribute to the development and expression of autism but are less well characterized, with many likely still undiscovered. These environmental contributors and their interactions with genetics represent modifiable factors, and intervention targets that can inform strategies to improve outcomes for individuals with autism. Observations in people and preclinical model systems indicate altered prenatal and early-life brain development in autism, including dysregulation of synaptic plasticity and immune function. However, disentangling the complex interplay between genetics and environmental factors that drive these changes in biological- and behavioral function remains a significant challenge. To address this research gap, NIH recently launched the Autism Data Science Initiative (ADSI). As part of this program, innovative new approaches that reflect an exposomics framework are being applied to the study of gene x environment (GxE) interactions in autism. This includes the application of advanced data science tools, such as machine learning (ML), artificial intelligence (AI), and novel statistical methods, to extant data derived from human epidemiology and clinical settings, with the goal of bridging complementary datasets for unprecedented insight. Alongside these efforts, new approach methodologies (NAMs), such as human-iPSC derived neurons and brain organoids, are being leveraged to study biological responses to neurodevelopmental toxicants or pharmacological treatments in the context of genetic susceptibility. These mechanistic studies have derived samples from well characterized human cohorts with existing genetic-, phenotypic-, and brain imaging data, potentially allowing for discovery across the translational spectrum. In developing this program, it was recognized that replication and validation of biomedical research findings is paramount to scientific rigor and advancement. In a first of its kind effort, this has been operationalized in ADSI through the incorporation of project-paired verification centers aimed at validating data science approaches and reproducing findings across studies. Each research project is further informed by a community engagement plan tailored to its respective scientific goals. ADSI research efforts are on a uniquely accelerated timeline (projects are budgeted for 2-3 years) and will be late in their second year during the Society of Toxicology's 2027 Annual Meeting. As such, each presentation will feature a significant amount of new data, with the session functioning as one of the earliest glimpses into this crosscutting initiative. Overall, this collection of presentations will provide a broad update on ADSI, the various strategies that ADSI investigators are using to examine toxicant exposure in autism, including large scale epidemiology, GxE interactions in brain organoids, and untargeted metabolomics, and the forefront of exposomics in autism research.
Session and Activity Type
Enter Note
Go to previous page in this tab
Event
